This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-0925v1 69/17/7022    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Spardy, N. Articles by Duensing, S. PubMed PubMed Citation Articles by Spardy, N. Articles by Duensing, S.

Human Papillomavirus 16 E7 Oncoprotein Attenuates DNA Damage Checkpoint Control by Increasing the Proteolytic Turnover of Claspin

¹ Biochemistry and Molecular Genetics Graduate Program, Departments of ² Pathology and ³ Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine; ⁴ Molecular Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; and ⁵ Division of Hematology and Oncology, Cincinnati's Children's Hospital Medical Center, Cincinnati, Ohio

Requests for reprints: Stefan Duensing, Molecular Virology Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Research Pavilion Suite 1.8, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-623-7719; Fax: 412-623-7715; E-mail: duensing{at}pitt.edu.

Key Words: HPV-16 E7 • DNA damage checkpoint • claspin

The human papillomavirus (HPV) 16 E7 oncoprotein has been reported previously to stimulate DNA damage and to activate host cell DNA damage checkpoints. How HPV-16 E7 maintains proliferation despite activated DNA damage checkpoints is incompletely understood. Here, we provide evidence that cells expressing the HPV-16 E7 oncoprotein can enter mitosis in the presence of DNA damage. We show that this activity of HPV-16 E7 involves attenuation of DNA damage checkpoint control by accelerating the proteolytic turnover of claspin. Claspin mediates the activation of CHK1 by ATR in response to replication stress, and its degradation plays a critical role in DNA damage checkpoint recovery. Expression of a nondegradable mutant of claspin was shown to inhibit mitotic entry in HPV-16 E7–expressing cells. Multiple components of the SCF^β-TrCP–based claspin degradation machinery were found deregulated in the presence of HPV-16 E7, including cullin 1, β-TrCP, Aurora A, and Polo-like kinase-1 (PLK1). In contrast, no difference in the expression level of the claspin deubiquitinating enzyme USP7 was detected. Levels of Aurora A and PLK1 as well as phosphorylated PLK1 at threonine 210, a prerequisite for DNA damage checkpoint recovery, remained detectable following replication stress in HPV-16 E7–expressing cells but not in control cells. In summary, our results suggest that the HPV-16 E7 oncoprotein alleviates DNA damage checkpoint responses and promotes mitotic entry by accelerating claspin degradation through a mechanism that involves deregulation of components of the SCF^β-TrCP–based claspin degradation machinery. [Cancer Res 2009;69(17):7022–9]